ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2019
Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nanoparticles based on photothermal effects in the treatment of hepatocellular carcinoma (HCC): a meta-analysis and systematic review.BMC cancer · 2026Pooled it
- Next-Generation Liposomal and Nanoparticle-Based Systems for Glioblastoma: Molecular Targeting Strategies to Overcome the Blood-Brain Barrier.International journal of molecular sciences · 2026Review
- Rational design of lipid-based nanoparticles for targeted anticancer therapies.Drug delivery and translational research · 2026Review
- Narrowing of glioma vascular caliber via chronic VEGFR2 blockade improves the uniformity of focused ultrasound-mediated small molecule drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Tumor microenvironment-specific nanomedicine: from biology-driven to multi-omics-guided precision engineering.Journal of hematology & oncology · 2026Review
- Precision Nanotechnology: Revolutionizing Therapeutic Strategies Against Drug-Resistant Breast Cancer.Annals of biomedical engineering · 2026Review
- Artificial intelligence empowered biomaterials for cancer therapy: From rational design to clinical translation.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Liposome-Encapsulated Carfilzomib as a Radiosensitizer in Solid Tumors.Molecular pharmaceutics · 2026Article
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- Light-responsive nanotherapeutic carbon dots: a next generation tool for cancer phototherapy.Journal of the National Cancer Center · 2026Review
- Comprehensive analysis of the TGF-β signaling pathway: molecular mechanisms, disease drivers, and frontiers in clinical translation.Frontiers in immunology · 2026Review
- Breaking the Barrier of Tumor Hypoxia: Oxygen-Enhancing Nano Biomaterials in Cancer Therapy.International journal of nanomedicine · 2026Review
- Tumor Microenvironment-Responsive Nanomedicine: Monitoring and Modulating the Tumor Microenvironment for Precision Cancer Therapy.International journal of nanomedicine · 2026Review
- Nanotechnology for immuno-oncology.Nature cancer · 2025Review
- Simulation of the Diffusion Characteristics of Multifunctional Nanocarriers in Tumor Tissues Using Lattice Gas Automata and the Lattice Boltzmann Method.Bioengineering (Basel, Switzerland) · 2025Article
- Novel Insights Into the Intratendinous Pressure Behavior of the Achilles Tendon in Athletes.Sports health · 2025Observational
- Exosomes: a double-edged sword in cancer immunotherapy.MedComm · 2025Review
- Sirtuins as Key Regulators in Pancreatic Cancer: Insights into Signaling Mechanisms and Therapeutic Implications.Cancers · 2024Review
- Curvature-mediated rapid extravasation and penetration of nanoparticles against interstitial fluid pressure for improved drug delivery.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeutics.Nature nanotechnology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
A major challenge in the development of cancer nanomedicine is the inability for nanomaterials to efficiently penetrate and deliver therapeutic agents into solid tumors. Previous studies have shown that tumor vasculature and extracellular matrix regulate the transvascular and interstitial transport of nanoparticles, both critical for successfully delivering nanomedicine into solid tumors. Within the malignant tumor microenvironment, blood vessels are morphologically abnormal and functionally exhibit substantial permeability. Furthermore, the tumor extracellular matrix (ECM), unlike that of the normal tissue parenchyma, is densely packed with collagen. These pathophysiological properties greatly impede intratumoral delivery of nanomaterials. By using an antivascular endothelial growth factor receptor antibody, DC101, and an antitransforming growth factor β1 (TGF-β1) antibody, normalization of the tumor vasculature and ECM is achieved, respectively, in a syngeneic murine glioma model. This normalization effect results in a more organized vascular network, improves tissue perfusion, and reduces collagen density, all of which contribute to enhanced nanoparticle delivery and distribution within tumors. These findings suggest that combined vascular and ECM normalization strategies can be used to remodel the tumor microenvironment and improve nanomedicine delivery into solid tumors, which has significant implications for developing more effective combinational therapeutic strategies using cancer nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.